US5506242A
(en)
*
|
1993-01-06 |
1996-04-09 |
Ciba-Geigy Corporation |
Arylsufonamido-substituted hydroxamic acids
|
US5646167A
(en)
*
|
1993-01-06 |
1997-07-08 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamix acids
|
US5552419A
(en)
*
|
1993-01-06 |
1996-09-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
GB9411598D0
(en)
*
|
1994-06-09 |
1994-08-03 |
Hoffmann La Roche |
Hydroxamic acid derivatives
|
AU690703B2
(en)
*
|
1994-06-22 |
1998-04-30 |
British Biotech Pharmaceuticals Limited |
Metalloproteinase inhibitors
|
US5817822A
(en)
*
|
1994-06-24 |
1998-10-06 |
Novartis Corporation |
Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
|
US5519060A
(en)
*
|
1995-01-17 |
1996-05-21 |
The Trustees Of The University Of Pennsylvania |
Sulfonamide-based compositions and methods
|
US5863949A
(en)
*
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
JP3053222B2
(ja)
*
|
1995-04-20 |
2000-06-19 |
ファイザー・インコーポレーテッド |
Mmpおよびtnf抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
|
WO1996033968A1
(fr)
*
|
1995-04-25 |
1996-10-31 |
Fuji Yakuhin Kogyo Kabushiki Kaisha |
Inhibiteur des metalloproteinases, tres soluble dans l'eau
|
US5728712A
(en)
*
|
1995-05-19 |
1998-03-17 |
Chiroscience Limited |
3,4-disubstituted-phenylsulphonamides and their therapeutic use
|
US6124333A
(en)
*
|
1995-06-22 |
2000-09-26 |
British Biotech Pharmaceuticals Limited |
Metalloproteinase inhibitors
|
KR980009238A
(ko)
|
1995-07-28 |
1998-04-30 |
우에노 도시오 |
설포닐아미노산 유도체
|
JPH11511137A
(ja)
*
|
1995-08-08 |
1999-09-28 |
ファイブロゲン,インコーポレーテッド |
コラーゲンの過剰生産に関係した疾患を治療するためのc−プロテイナーゼ阻害剤
|
ATE226936T1
(de)
*
|
1995-08-08 |
2002-11-15 |
Ono Pharmaceutical Co |
Hydroxamsäurederivate verwendbar zur hemmung von gelatinase
|
CA2237590C
(en)
|
1995-11-13 |
2011-07-19 |
Hoechst Aktiengesellschaft |
Cyclic and heterocyclic n-substituted .alpha.-iminohydroxamic and -carboxylic acids
|
DE69624262T2
(de)
|
1995-11-17 |
2003-09-11 |
Warner-Lambert Co., Morris Plains |
Sulfonamidinhibitoren von matrix metalloproteinasen
|
WO1997019682A1
(en)
*
|
1995-12-01 |
1997-06-05 |
Synaptic Pharmaceutical Corporation |
Aryl sulfonamide and sulfamide derivatives and uses thereof
|
GEP20012388B
(en)
*
|
1995-12-08 |
2001-03-25 |
Agouron Pharma |
Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
|
US6500948B1
(en)
|
1995-12-08 |
2002-12-31 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
|
US5753653A
(en)
|
1995-12-08 |
1998-05-19 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
TW453995B
(en)
*
|
1995-12-15 |
2001-09-11 |
Novartis Ag |
Certain alpha-substituted arylsulfonamido acetohydroxamic acids
|
PT780386E
(pt)
*
|
1995-12-20 |
2003-02-28 |
Hoffmann La Roche |
Inibidores de metaloprotease de matriz
|
JP4358908B2
(ja)
*
|
1996-01-02 |
2009-11-04 |
アヴェンティス ファーマシューティカルズ インコーポレイテッド |
置換(アリール、ヘテロアリール、アリールメチル又はヘテロアリールメチル)ヒドロキサム酸化合物
|
KR100338861B1
(ko)
*
|
1996-01-23 |
2003-02-20 |
시오노기세이야쿠가부시키가이샤 |
술폰화아미노산유도체및이를함유한메탈로프로테이나제저해제
|
US6919375B1
(en)
|
1996-01-23 |
2005-07-19 |
Shionogi & Co., Ltd. |
Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
|
US5994351A
(en)
*
|
1998-07-27 |
1999-11-30 |
Pfizer Inc. |
Arylsulfonylamino hydroxamic acid derivatives
|
FR2748026B1
(fr)
*
|
1996-04-26 |
1998-06-05 |
Adir |
Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US5854275A
(en)
*
|
1996-05-16 |
1998-12-29 |
Pfizer Inc. |
Cyclic imide derivatives
|
WO1997045402A1
(fr)
*
|
1996-05-24 |
1997-12-04 |
Ono Pharmaceutical Co., Ltd. |
Derives de phenylsulfonamide
|
EP0818442A3
(en)
*
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
CN1238688A
(zh)
*
|
1996-07-22 |
1999-12-15 |
孟山都公司 |
硫羟磺酰胺金属蛋白酶抑制剂
|
WO1998007697A1
(en)
*
|
1996-08-23 |
1998-02-26 |
Pfizer Inc. |
Arylsulfonylamino hydroxamic acid derivatives
|
DK0925303T3
(da)
*
|
1996-08-28 |
2003-02-24 |
Procter & Gamble |
Phosphinsyreamider som matrixmetalloproteaseinhibitorer
|
HUP0000210A3
(en)
*
|
1996-08-28 |
2001-07-30 |
Procter And Gamble Co Cincinna |
Heterocyclic compounds as metalloprotease inhibitors and use of them for producing pharmaceutical compisitions
|
BR9712792A
(pt)
*
|
1996-08-28 |
1999-12-14 |
Procter & Gamble |
Inibidores de metaloprotease bidentada.
|
KR100323272B1
(ko)
*
|
1996-08-28 |
2002-02-06 |
데이비드 엠 모이어 |
치환된 시클릭 아민 메탈로프로테아제 저해제
|
IL128663A0
(en)
*
|
1996-08-28 |
2000-01-31 |
Procter & Gamble |
1,4-heterocyclic metalloprotease inhibitors
|
PT927183E
(pt)
*
|
1996-08-28 |
2004-12-31 |
Procter & Gamble |
Inibidores espirociclicos de metaloproteases
|
US6872742B2
(en)
*
|
1996-08-28 |
2005-03-29 |
The Procter & Gamble Company |
Substituted cyclic amine metalloprotease inhibitors
|
ATE227274T1
(de)
*
|
1996-08-28 |
2002-11-15 |
Procter & Gamble |
1,3-diheterozyklische metalloprotease inhibitoren
|
AU736347B2
(en)
|
1996-09-04 |
2001-07-26 |
Warner-Lambert Company |
Compounds for and a method of inhibiting matrix metalloproteinases
|
US6624177B1
(en)
|
1996-09-04 |
2003-09-23 |
Warner-Lambert Company |
Matrix metalloproteinase inhibitors and their therapeutic uses
|
EP0931045A1
(en)
*
|
1996-09-04 |
1999-07-28 |
Warner-Lambert Company |
Matrix metalloproteinase inhibitors and their therapeutic uses
|
US5977408A
(en)
*
|
1996-10-16 |
1999-11-02 |
American Cyanamid Company |
Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
US6228869B1
(en)
|
1996-10-16 |
2001-05-08 |
American Cyanamid Company |
Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
AU743901B2
(en)
*
|
1996-10-16 |
2002-02-07 |
Wyeth Holdings Corporation |
Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors
|
US5929097A
(en)
*
|
1996-10-16 |
1999-07-27 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
NZ335029A
(en)
*
|
1996-10-16 |
2000-10-27 |
American Cyanamid Co |
Ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase (MMP) and TACE (tumor necrosis factor, TNF, alpha converting enzyme) inhibitors
|
BR9712524A
(pt)
*
|
1996-10-16 |
1999-10-19 |
American Cyanamid Co |
Acidos beta-sulfonamido-hidroxmicos como inibidores de tace e de metaloproteinase de matriz
|
US5962481A
(en)
*
|
1996-10-16 |
1999-10-05 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
US6548524B2
(en)
|
1996-10-16 |
2003-04-15 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
ES2166102T3
(es)
*
|
1996-10-16 |
2002-04-01 |
American Cyanamid Co |
Preparacion y utilizacion de acidos orto-sulfonamidoarilhidroxamicos como inhibidores de las metaloproteinasas matriz y los tace.
|
DE69710204T2
(de)
*
|
1996-10-22 |
2002-10-24 |
Pharmacia & Upjohn Co., Kalamazoo |
Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
|
US6174915B1
(en)
|
1997-03-25 |
2001-01-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
US6008243A
(en)
*
|
1996-10-24 |
1999-12-28 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
|
AU5426398A
(en)
|
1996-10-28 |
1998-05-22 |
Versicor Inc |
Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
|
US6281245B1
(en)
|
1996-10-28 |
2001-08-28 |
Versicor, Inc. |
Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
|
KR20000057595A
(ko)
*
|
1996-12-17 |
2000-09-25 |
후지야마 아키라 |
Mmp 또는 tnf의 억제제로서 피페라진 화합물
|
EP0946166B1
(en)
|
1996-12-17 |
2004-02-18 |
Warner-Lambert Company LLC |
Use of matrix metalloproteinase inhibitors for promoting wound healing
|
EP1366765A1
(en)
*
|
1996-12-17 |
2003-12-03 |
Warner-Lambert Company Llc |
Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
|
UA59384C2
(uk)
|
1996-12-20 |
2003-09-15 |
Пфайзер, Інк. |
Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
|
ES2224277T3
(es)
*
|
1997-01-06 |
2005-03-01 |
Pfizer Inc. |
Derivados de sulfonas ciclicas.
|
JP2001509810A
(ja)
*
|
1997-01-17 |
2001-07-24 |
ファルマシア・アンド・アップジョン・カンパニー |
Mmpインヒビターとしてのビス−スルホンアミドヒドロキサム酸
|
JP4456183B2
(ja)
|
1997-01-22 |
2010-04-28 |
アベンテイス・フアーマシユーチカルズ・インコーポレーテツド |
置換β−チオカルボン酸類
|
US6376506B1
(en)
|
1997-01-23 |
2002-04-23 |
Syntex (U.S.A.) Llc |
Sulfamide-metalloprotease inhibitors
|
ATE223909T1
(de)
*
|
1997-01-23 |
2002-09-15 |
Hoffmann La Roche |
Sulfamide-metalloprotease inhibitoren
|
ZA98376B
(en)
*
|
1997-01-23 |
1998-07-23 |
Hoffmann La Roche |
Sulfamide-metalloprotease inhibitors
|
WO1998033777A1
(fr)
*
|
1997-01-31 |
1998-08-06 |
Shionogi & Co., Ltd. |
Composes ayant une activite inhibant la metalloprotease
|
DK0977733T3
(da)
*
|
1997-02-03 |
2003-11-24 |
Pfizer Prod Inc |
Arylsulfonylaminohydroxamsyrederivater
|
KR20000070923A
(ko)
|
1997-02-11 |
2000-11-25 |
디. 제이. 우드, 스피겔 알렌 제이 |
아릴설포닐 하이드록삼산 유도체
|
US6172057B1
(en)
|
1997-02-27 |
2001-01-09 |
American Cyanamid Company |
N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
|
US6197791B1
(en)
|
1997-02-27 |
2001-03-06 |
American Cyanamid Company |
N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
|
IL131257A0
(en)
*
|
1997-02-27 |
2001-01-28 |
American Cyanamid Co |
N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl sulfinyl or sulfonyl)-3-substituted alkyl aryl or heteroarylamides as matrix metalloproteinase inhibitors
|
US6696449B2
(en)
|
1997-03-04 |
2004-02-24 |
Pharmacia Corporation |
Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
|
DE69828783T2
(de)
*
|
1997-03-04 |
2006-01-12 |
Pharmacia Corp. |
Hydroxamsäure-sulfonamid-derivate mit amidiertem aromatischen ring
|
KR20000075954A
(ko)
|
1997-03-04 |
2000-12-26 |
죤 에이치. 뷰센 |
N-히드록시 4-술포닐 부탄아미드 화합물
|
US7115632B1
(en)
|
1999-05-12 |
2006-10-03 |
G. D. Searle & Co. |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
US6794511B2
(en)
|
1997-03-04 |
2004-09-21 |
G. D. Searle |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
GB9706255D0
(en)
|
1997-03-26 |
1997-05-14 |
Smithkline Beecham Plc |
Novel compounds
|
US5985900A
(en)
*
|
1997-04-01 |
1999-11-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
US5756545A
(en)
*
|
1997-04-21 |
1998-05-26 |
Warner-Lambert Company |
Biphenysulfonamide matrix metal alloproteinase inhibitors
|
DE59802394D1
(de)
|
1997-05-09 |
2002-01-24 |
Hoechst Ag |
Substituierte Diaminocarbonsäuren
|
AU7294098A
(en)
*
|
1997-05-09 |
1998-11-27 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
DE19719621A1
(de)
|
1997-05-09 |
1998-11-12 |
Hoechst Ag |
Sulfonylaminocarbonsäuren
|
DE19719817A1
(de)
*
|
1997-05-13 |
1998-11-19 |
Hoechst Ag |
Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
|
US6300514B1
(en)
|
1997-06-25 |
2001-10-09 |
Ono Pharmaceutical Co., Ltd. |
Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
|
IL134273A0
(en)
|
1997-07-31 |
2001-04-30 |
Procter & Gamble |
Acyclic metalloprotease inhibitors
|
SI1003720T1
(en)
*
|
1997-08-08 |
2004-06-30 |
Pfizer Products Inc. |
Aryloxyarylsulfonylamino hydroxamic acid derivatives
|
EA002490B1
(ru)
*
|
1997-08-08 |
2002-06-27 |
Пфайзер Продактс Инк. |
Производные арилоксиарилсульфониламиногидроксамовой кислоты
|
US6130220A
(en)
*
|
1997-10-16 |
2000-10-10 |
Syntex (Usa) Inc. |
Sulfamide-metalloprotease inhibitors
|
US20010039287A1
(en)
|
1997-11-14 |
2001-11-08 |
Thomas E Barta |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
US6750228B1
(en)
*
|
1997-11-14 |
2004-06-15 |
Pharmacia Corporation |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
US6541489B1
(en)
|
1997-11-14 |
2003-04-01 |
G. D. Searle & Company |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
GB9725782D0
(en)
*
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
US6335329B1
(en)
|
1997-12-19 |
2002-01-01 |
Amgen Inc. |
Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
|
US6107291A
(en)
*
|
1997-12-19 |
2000-08-22 |
Amgen Inc. |
Azepine or larger medium ring derivatives and methods of use
|
GB9801690D0
(en)
*
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
US6071903A
(en)
*
|
1998-01-27 |
2000-06-06 |
American Cyanamid Company |
2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
|
PL342548A1
(en)
*
|
1998-02-19 |
2001-06-18 |
American Cyanamid Co |
N-hydroxy-2-(alkyl-, aryl- or heteroarylsulphanyl-, sulphinyl- or sulphonyl)-3-substituted alkyl-, aryl- or heteroarylamides as inhibitors of matrix metaloproteinases
|
US6703536B2
(en)
|
1998-03-12 |
2004-03-09 |
The Procter & Gamble Company |
Disposable absorbent article having a skin care composition containing an enzyme inhibitor
|
AU3079799A
(en)
|
1998-03-12 |
1999-09-27 |
Procter & Gamble Company, The |
Protease inhibitors in absorbent articles
|
ID26829A
(id)
*
|
1998-04-03 |
2001-02-15 |
Sankyo Co |
Turunan-turunan sulfonamida
|
PA8469501A1
(es)
*
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
US6329418B1
(en)
|
1998-04-14 |
2001-12-11 |
The Procter & Gamble Company |
Substituted pyrrolidine hydroxamate metalloprotease inhibitors
|
BR9912085A
(pt)
|
1998-07-16 |
2001-04-10 |
Aventis Pharma Gmbh |
Derivados de ácido fosfìnico e ácido fosfÈnico como medicamentos
|
NZ525513A
(en)
|
1998-08-07 |
2004-09-24 |
Pont Pharmaceuticals Du |
Succinoylamino lactams as inhibitors of Abeta protein production
|
HRP990246A2
(en)
|
1998-08-07 |
2000-06-30 |
Du Pont Pharm Co |
Succinoylamino benzodiazepines as inhibitors of a beta protein production
|
FR2782080B1
(fr)
*
|
1998-08-10 |
2001-01-05 |
Adir |
Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US6509337B1
(en)
|
1998-09-17 |
2003-01-21 |
Pfizer Inc. |
Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
|
DE19851184A1
(de)
|
1998-11-06 |
2000-05-11 |
Aventis Pharma Gmbh |
N-Arylsulfonyl-aminosäure-omega-amide
|
US6737038B1
(en)
|
1998-11-12 |
2004-05-18 |
Bristol-Myers Squibb Company |
Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
|
WO2000028331A1
(en)
*
|
1998-11-12 |
2000-05-18 |
Du Pont Pharmaceuticals Company |
Use of radioligands to screen inhibitors of amyloid-beta peptide production
|
CA2355902A1
(en)
*
|
1998-12-22 |
2000-06-29 |
F. Hoffmann-La Roche Ag |
Sulfonamide hydroxamates
|
US6492394B1
(en)
|
1998-12-22 |
2002-12-10 |
Syntex (U.S.A.) Llc |
Sulfonamide hydroxamates
|
AR022423A1
(es)
*
|
1999-01-27 |
2002-09-04 |
American Cyanamid Co |
Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
|
US6544984B1
(en)
|
1999-01-27 |
2003-04-08 |
American Cyanamid Company |
2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
|
US6225311B1
(en)
|
1999-01-27 |
2001-05-01 |
American Cyanamid Company |
Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
|
US6326516B1
(en)
|
1999-01-27 |
2001-12-04 |
American Cyanamid Company |
Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
|
US6946473B2
(en)
*
|
1999-01-27 |
2005-09-20 |
Wyeth Holdings Corporation |
Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
|
US6340691B1
(en)
|
1999-01-27 |
2002-01-22 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
|
CN1178915C
(zh)
|
1999-01-27 |
2004-12-08 |
惠氏控股有限公司 |
含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途
|
US6277885B1
(en)
|
1999-01-27 |
2001-08-21 |
American Cyanamid Company |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
US6762178B2
(en)
|
1999-01-27 |
2004-07-13 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
US6313123B1
(en)
|
1999-01-27 |
2001-11-06 |
American Cyanamid Company |
Acetylenic sulfonamide thiol tace inhibitors
|
US6753337B2
(en)
|
1999-01-27 |
2004-06-22 |
Wyeth Holdings Corporation |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
US6200996B1
(en)
|
1999-01-27 |
2001-03-13 |
American Cyanamid Company |
Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
|
US6800646B1
(en)
|
1999-02-08 |
2004-10-05 |
Pharmacia Corporation |
Sulfamato hydroxamic acid metalloprotease inhibitor
|
SK11352001A3
(sk)
|
1999-02-08 |
2002-09-10 |
G. D. Searle & Co. |
Metaloproteázový inhibítor kyselina sulfamátohydroxámová
|
US6506936B1
(en)
|
1999-02-25 |
2003-01-14 |
Fibrogen, Inc. |
N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
|
IL145085A0
(en)
|
1999-03-03 |
2002-06-30 |
Procter & Gamble |
Dihetero-substituted metalloprotease inhibitors
|
WO2000051975A1
(en)
*
|
1999-03-03 |
2000-09-08 |
The Procter & Gamble Company |
Alkenyl- and alkynyl-containing metalloprotease inhibitors
|
DK1041072T3
(da)
*
|
1999-03-31 |
2003-11-10 |
Pfizer Prod Inc |
Dioxocyclopentylhydroxamsyrer
|
AU4249700A
(en)
*
|
1999-04-19 |
2000-11-02 |
Sumitomo Pharmaceuticals Company, Limited |
Hydroxamic acid derivative
|
WO2000073295A1
(en)
*
|
1999-05-28 |
2000-12-07 |
Pfizer Products Inc. |
3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides
|
HN2000000052A
(es)
*
|
1999-05-28 |
2001-02-02 |
Pfizer Prod Inc |
Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
|
US6511993B1
(en)
|
1999-06-03 |
2003-01-28 |
Kevin Neil Dack |
Metalloprotease inhibitors
|
GB9912961D0
(en)
*
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
GB9918684D0
(en)
*
|
1999-08-09 |
1999-10-13 |
Novartis Ag |
Organic compounds
|
EP1081137A1
(en)
|
1999-08-12 |
2001-03-07 |
Pfizer Products Inc. |
Selective inhibitors of aggrecanase in osteoarthritis treatment
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
WO2001062715A1
(en)
*
|
2000-02-24 |
2001-08-30 |
Smithkline Beecham P.L.C. |
Novel cd23 inhibitors
|
US6465508B1
(en)
|
2000-02-25 |
2002-10-15 |
Wyeth |
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
|
US6458822B2
(en)
|
2000-03-13 |
2002-10-01 |
Pfizer Inc. |
2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
|
US6455587B1
(en)
*
|
2000-03-15 |
2002-09-24 |
Pharmacor Inc. |
Amino acid derivatives as HIV aspartyl protease inhibitors
|
CA2401728A1
(en)
|
2000-03-21 |
2001-09-27 |
The Procter & Gamble Company |
Difluorobutyric acid metalloprotease inhibitors
|
EP1265864A1
(en)
|
2000-03-21 |
2002-12-18 |
The Procter & Gamble Company |
Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
|
JP2003528078A
(ja)
*
|
2000-03-21 |
2003-09-24 |
ザ プロクター アンド ギャンブル カンパニー |
炭素環式側鎖を含有するメタロプロテアーゼ阻害剤
|
CN1418210A
(zh)
*
|
2000-03-21 |
2003-05-14 |
宝洁公司 |
含有碳环侧链的n-取代金属蛋白酶抑制剂
|
CZ20023180A3
(cs)
*
|
2000-03-21 |
2003-02-12 |
The Procter And Gamble Company |
Metalloproteázové inhibitory zahrnující vedlejší heterocyklický řetězec
|
JP4074043B2
(ja)
|
2000-03-27 |
2008-04-09 |
株式会社資生堂 |
皮膚基底膜形成促進剤、人工皮膚形成促進剤及び人工皮膚の製造方法
|
EP1138680A1
(en)
|
2000-03-29 |
2001-10-04 |
Pfizer Products Inc. |
Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
|
US6713477B1
(en)
|
2000-04-19 |
2004-03-30 |
Sumitomo Pharmaceuticals Company, Limited |
Hydroxamic acid derivatives
|
US6495358B1
(en)
|
2000-04-19 |
2002-12-17 |
Wichita State University |
Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
|
US6683093B2
(en)
|
2000-05-12 |
2004-01-27 |
Pharmacia Corporation |
Aromatic sulfone hydroxamic acids and their use as protease inhibitors
|
JP2002047125A
(ja)
*
|
2000-05-26 |
2002-02-12 |
Shiseido Co Ltd |
皮脂分泌抑制用皮膚外用剤
|
BR0106717A
(pt)
|
2000-06-01 |
2002-04-16 |
Bristol Myers Squibb Pharma Co |
Compostos, composição farmacêutica e usos dos compostos de lactama inovadora
|
IL145209A0
(en)
|
2000-09-06 |
2002-06-30 |
Pfizer Prod Inc |
Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
|
EP1345612B1
(de)
|
2000-12-16 |
2005-03-16 |
Aventis Pharma Deutschland GmbH |
Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
|
MX349009B
(es)
|
2001-01-05 |
2017-07-06 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
|
FR2819252A1
(fr)
*
|
2001-01-11 |
2002-07-12 |
Servier Lab |
Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
FR2819253B1
(fr)
*
|
2001-01-11 |
2004-12-03 |
Servier Lab |
Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
GB0103303D0
(en)
*
|
2001-02-09 |
2001-03-28 |
Novartis Ag |
Organic compounds
|
KR100801121B1
(ko)
|
2001-04-10 |
2008-02-05 |
니뽄 신야쿠 가부시키가이샤 |
만성 관절 류마티즘 치료제
|
OA12602A
(en)
|
2001-05-11 |
2006-06-09 |
Pharmacia Corp |
Aromatic sulfone hydroxamates and their use as protease inhibitors.
|
US6887877B2
(en)
*
|
2001-06-11 |
2005-05-03 |
Virochem Pharma Inc. |
Compounds and methods for the treatment or prevention of Flavivirus infections
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
CN1610661A
(zh)
*
|
2001-11-01 |
2005-04-27 |
惠氏控股公司 |
用作基质金属蛋白酶和tace的抑制剂的丙二烯芳基磺酰胺异羟肟酸
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
US6933298B2
(en)
|
2001-12-08 |
2005-08-23 |
Aventis Pharma Deutschland Gmbh |
Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
|
PE20030701A1
(es)
*
|
2001-12-20 |
2003-08-21 |
Schering Corp |
Compuestos para el tratamiento de trastornos inflamatorios
|
US6716853B2
(en)
|
2002-03-02 |
2004-04-06 |
Aventis Pharma Deutschland Gmbh |
Cyclic N-substituted alpha-imino carboxylic acids for selective inhibition of collogenase
|
EP2275102B1
(en)
|
2002-03-13 |
2015-07-29 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
MXPA04010555A
(es)
|
2002-04-25 |
2005-02-17 |
Pharmacia Corp |
Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
|
AU2003223012A1
(en)
|
2002-04-26 |
2003-11-10 |
Pfizer Products Inc. |
Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
|
NI200300045A
(es)
|
2002-04-26 |
2005-07-08 |
Pfizer Prod Inc |
Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
|
ATE304015T1
(de)
|
2002-04-26 |
2005-09-15 |
Pfizer Prod Inc |
Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren
|
ATE308544T1
(de)
|
2002-04-26 |
2005-11-15 |
Pfizer Prod Inc |
N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren
|
WO2003104224A1
(en)
|
2002-06-10 |
2003-12-18 |
Pfizer Inc. |
Metabolites of prinomastat and their sythesis
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
AU2003253346A1
(en)
*
|
2002-07-29 |
2004-02-23 |
Novartis Ag |
Use or arylsulfonamido-substituted hydroxamid acid matrix metalloproteinase inhibitors for the treatment or prevention of toxemia
|
US7166609B2
(en)
|
2002-11-02 |
2007-01-23 |
Sanofi-Aventis Deutschland Gmbh |
Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases
|
OA12977A
(en)
|
2002-12-19 |
2006-10-13 |
Pfizer |
2-(1H-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthamic diseases.
|
US7199155B2
(en)
*
|
2002-12-23 |
2007-04-03 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
|
DE10300015A1
(de)
|
2003-01-03 |
2004-07-15 |
Aventis Pharma Deutschland Gmbh |
Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen
|
US6878404B2
(en)
*
|
2003-02-06 |
2005-04-12 |
Guardian Industries Corp. |
Method of depositing DLC on substrate
|
CA2516328A1
(en)
*
|
2003-02-18 |
2004-09-02 |
Pfizer Inc. |
Inhibitors of hepatitis c virus, compositions and treatments using the same
|
MXPA05009063A
(es)
|
2003-02-26 |
2005-12-12 |
Sugen Inc |
Compuestos de aminoheteroarilo como inhibidores de proteina cinasa.
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
ATE412655T1
(de)
|
2003-08-29 |
2008-11-15 |
Pfizer |
Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
DE10344936A1
(de)
*
|
2003-09-27 |
2005-04-21 |
Aventis Pharma Gmbh |
Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
|
JP5046649B2
(ja)
|
2003-11-19 |
2012-10-10 |
アレイ バイオファーマ、インコーポレイテッド |
Mekの二環系阻害剤及びその使用方法
|
US7671072B2
(en)
*
|
2003-11-26 |
2010-03-02 |
Pfizer Inc. |
Aminopyrazole derivatives as GSK-3 inhibitors
|
DE102004004974A1
(de)
|
2004-01-31 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
|
US7163942B2
(en)
|
2004-04-01 |
2007-01-16 |
Pfizer Inc. |
Sulfonamide compounds for the treatment of neurodegenerative disorders
|
WO2005108367A1
(en)
*
|
2004-05-03 |
2005-11-17 |
Envivo Pharmaceuticals, Inc. |
Compounds for treatment of neurodegenerative diseases
|
US20050277897A1
(en)
*
|
2004-06-14 |
2005-12-15 |
Ghannoum Ziad R |
Handpiece tip
|
EP1802341A1
(en)
|
2004-07-16 |
2007-07-04 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
|
ITFI20040174A1
(it)
*
|
2004-08-03 |
2004-11-03 |
Protera S R L |
Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
|
EA013678B1
(ru)
|
2004-08-26 |
2010-06-30 |
Пфайзер Инк. |
Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
JP5270336B2
(ja)
|
2005-05-18 |
2013-08-21 |
アレイ バイオファーマ、インコーポレイテッド |
Mekの複素環式阻害剤及びその使用方法
|
CN101849943A
(zh)
*
|
2005-06-06 |
2010-10-06 |
菲布罗根公司 |
使用HIFα稳定剂的改进的贫血治疗
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
AU2006292278B2
(en)
|
2005-09-20 |
2012-03-08 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2007121269A2
(en)
|
2006-04-11 |
2007-10-25 |
Ardea Biosciences, Inc. |
N-aryl-n'alkyl sulfamides as mek inhibitors
|
EP2012786B1
(en)
|
2006-04-18 |
2010-10-06 |
Ardea Biosciences, Inc. |
Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
|
ATE509956T1
(de)
*
|
2006-06-08 |
2011-06-15 |
Helmholtz Zentrum Muenchen |
Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie
|
CA2672815A1
(en)
|
2006-12-15 |
2008-06-26 |
Pfizer Products Inc. |
Benzimidazole derivatives for use in treating abnormal cell growth
|
CA2675358C
(en)
|
2007-01-19 |
2016-01-05 |
Ardea Biosciences, Inc. |
Inhibitors of mek
|
NZ580372A
(en)
|
2007-04-18 |
2012-01-12 |
Pfizer Prod Inc |
Pyrimidine and triazine derivatives including a sulfonamide group for the treatment of abnormal cell growth such as cancer
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
UA99731C2
(ru)
|
2007-07-30 |
2012-09-25 |
Ардеа Биосайенсис, Инк |
Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
|
CA2708281A1
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
KR101195329B1
(ko)
|
2007-12-19 |
2012-10-29 |
제넨테크, 인크. |
5-아닐리노이미다조피리딘 및 사용 방법
|
NZ586575A
(en)
|
2007-12-21 |
2012-03-30 |
Genentech Inc |
Azaindolizines and methods of use
|
MX2010007419A
(es)
|
2008-01-04 |
2010-11-12 |
Intellikine Inc |
Ciertas entidades quimicas, composiciones y metodos.
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤および使用方法
|
US20090258865A1
(en)
|
2008-03-28 |
2009-10-15 |
Hale Biopharma Ventures, Llc |
Administration of benzodiazepine compositions
|
JP5492189B2
(ja)
*
|
2008-04-09 |
2014-05-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ccr10アンタゴニストである2−スルホニルアミノ−4−ヘテロアリールブチロアミド
|
BRPI0915231A2
(pt)
|
2008-07-08 |
2018-06-12 |
Intellikine Inc |
compostos inibidores de quinase e métodos de uso
|
US8476410B2
(en)
|
2008-10-16 |
2013-07-02 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
IL295601B1
(en)
|
2009-02-05 |
2024-07-01 |
Immunogen Inc |
History of benzodiazepines and processes for their preparation
|
TW201041892A
(en)
|
2009-02-09 |
2010-12-01 |
Supergen Inc |
Pyrrolopyrimidinyl Axl kinase inhibitors
|
EP2400985A2
(en)
|
2009-02-25 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401613A2
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
JP2012519281A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
EP2411366B8
(en)
|
2009-03-27 |
2015-07-15 |
Ardea Biosciences, Inc. |
Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
|
JP2012523438A
(ja)
|
2009-04-10 |
2012-10-04 |
タフツ メディカル センター インコーポレイテッド |
メタロプロテイナーゼ−1(mmp−1)によるpar−1活性化
|
CA2757761A1
(en)
*
|
2009-05-01 |
2010-11-04 |
Raqualia Pharma Inc. |
Sulfamoyl benzoic acid derivatives as trpm8 antagonists
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン, エルエルシー |
複素環式化合物およびその使用
|
EP2459191A1
(en)
|
2009-07-31 |
2012-06-06 |
OSI Pharmaceuticals, LLC |
Mtor inhibitor and angiogenesis inhibitor combination therapy
|
MX2012002066A
(es)
|
2009-08-17 |
2012-03-29 |
Intellikine Inc |
Compuestos heterociclicos y usos de los mismos.
|
ITTO20090648A1
(it)
*
|
2009-08-19 |
2011-02-20 |
Istituto Naz Per La Ricerca Sul Cancro |
Inibitori di adam17 atti a modulare il rilascio di alcam (cd166) solubile in cellule tumorali e loro uso nel trattamento terapeutico del carcinoma ovarico epiteliale (eoc)
|
JP2013503846A
(ja)
|
2009-09-01 |
2013-02-04 |
ファイザー・インク |
ベンズイミダゾール誘導体
|
ES2534358T3
(es)
|
2009-10-13 |
2015-04-21 |
Allomek Therapeutics, Llc |
Inhibidores novedosos de MEK útiles en el tratamiento de enfermedades
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
HUE035059T2
(hu)
|
2009-11-05 |
2018-05-02 |
Rhizen Pharmaceuticals S A |
Új benzopirán-kinát modulátorok
|
CN105001334A
(zh)
|
2010-02-10 |
2015-10-28 |
伊缪诺金公司 |
Cd20抗体及其用途
|
EP3150610B1
(en)
|
2010-02-12 |
2019-07-31 |
Pfizer Inc |
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
|
CA2783656A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011109584A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
IT1401253B1
(it)
|
2010-04-23 |
2013-07-18 |
Uni Degli Studi Carlo Bo Urbino |
Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
|
KR101871436B1
(ko)
|
2010-05-17 |
2018-06-27 |
인코젠 쎄라퓨틱스 프라이빗 리미티드 |
단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
|
CA2799579A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
CA2802857C
(en)
|
2010-06-16 |
2018-09-11 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Antibodies to endoplasmin and their use
|
WO2012052948A1
(en)
|
2010-10-20 |
2012-04-26 |
Pfizer Inc. |
Pyridine- 2- derivatives as smoothened receptor modulators
|
CA2817577A1
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
TWI546305B
(zh)
|
2011-01-10 |
2016-08-21 |
英菲尼提製藥股份有限公司 |
製備異喹啉酮之方法及異喹啉酮之固體形式
|
AU2012212075A1
(en)
|
2011-02-02 |
2013-07-18 |
Amgen Inc. |
Methods and compositons relating to inhibition of IGF-1R
|
BR112013020540B1
(pt)
|
2011-02-15 |
2020-12-29 |
Immunogen, Inc |
métodos para preparação de conjugados compreendendo agente de ligação à célula conjugado a composto citotóxico com grupo ligante
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
EP2699598B1
(en)
|
2011-04-19 |
2019-03-06 |
Pfizer Inc |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
MX365160B
(es)
|
2011-05-04 |
2019-05-24 |
Rhizen Pharmaceuticals Sa |
Compuestos novedosos como moduladores de proteína cinasas.
|
EP2520573A1
(en)
*
|
2011-05-06 |
2012-11-07 |
Westfälische Wilhelms-Universität Münster |
Compounds with matrix-metalloproteinase inhibitory activity
|
US9023318B2
(en)
|
2011-06-08 |
2015-05-05 |
Siemens Medical Solutions Usa, Inc. |
Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
|
ES2917973T3
(es)
|
2011-06-14 |
2022-07-12 |
Neurelis Inc |
Administración de benzodiacepina
|
AU2012284091B2
(en)
|
2011-07-19 |
2015-11-12 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
AU2012284088B2
(en)
|
2011-07-19 |
2015-10-08 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
DK3409278T3
(da)
|
2011-07-21 |
2020-11-09 |
Sumitomo Dainippon Pharma Oncology Inc |
Heterocykliske proteinkinaseinhibitorer
|
EP2751093A1
(en)
|
2011-08-29 |
2014-07-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
PE20141228A1
(es)
|
2011-09-22 |
2014-10-01 |
Pfizer |
Derivados de pirrolopirimidina y purina
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
CA2848842C
(en)
|
2011-10-04 |
2020-09-29 |
King's College London |
Ige anti -hmw-maa antibody
|
MX2014005570A
(es)
|
2011-11-08 |
2014-05-30 |
Pfizer |
El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.
|
EP3345624A1
(en)
|
2012-02-22 |
2018-07-11 |
The Regents Of The University Of Colorado |
Bouvardin derivatives and therapeutic uses thereof
|
US9452215B2
(en)
|
2012-02-22 |
2016-09-27 |
The Regents Of The University Of Colorado |
Bourvadin derivatives and therapeutic uses thereof
|
US9815831B2
(en)
|
2012-03-30 |
2017-11-14 |
Rhizen Pharmaceuticals Sa |
3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
HUE043552T2
(hu)
|
2012-06-08 |
2019-09-30 |
Sutro Biopharma Inc |
Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
|
EP2863955B1
(en)
|
2012-06-26 |
2016-11-23 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
EP2887965A1
(en)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Cytotoxic benzodiazepine derivatives
|
BR112015004022B1
(pt)
|
2012-08-31 |
2023-04-25 |
Sutro Biopharma, Inc |
Aminoácidos modificados compreendendo um grupo azido
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
CN105102000B
(zh)
|
2012-11-01 |
2021-10-22 |
无限药品公司 |
使用pi3激酶亚型调节剂的癌症疗法
|
US9901647B2
(en)
|
2013-02-28 |
2018-02-27 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP3566750A3
(en)
|
2013-02-28 |
2020-04-08 |
ImmunoGen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
KR102334260B1
(ko)
|
2013-03-14 |
2021-12-02 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Jak2 및 alk2 억제제 및 이들의 사용 방법
|
EP2970121B1
(en)
|
2013-03-15 |
2017-12-13 |
Araxes Pharma LLC |
Covalent inhibitors of kras g12c
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
EP2970194A1
(en)
|
2013-03-15 |
2016-01-20 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
EP3003309B1
(en)
|
2013-05-30 |
2020-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
HUE036600T2
(hu)
|
2013-10-03 |
2018-07-30 |
Kura Oncology Inc |
ERK inhibitorok és alkalmazási eljárások
|
SG10201902074UA
(en)
|
2013-10-04 |
2019-04-29 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
BR112016008016B8
(pt)
|
2013-10-10 |
2023-09-26 |
Araxes Pharma Llc |
Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditos compostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ou nras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dos ditos compostos
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
JP6574203B2
(ja)
|
2014-04-30 |
2019-09-11 |
ファイザー・インク |
シクロアルキル結合ジヘテロ環誘導体
|
CN106559991B
(zh)
|
2014-06-19 |
2019-09-20 |
阿里亚德医药股份有限公司 |
用于激酶抑制的杂芳基化合物
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
JP6811706B2
(ja)
|
2014-07-31 |
2021-01-13 |
ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー |
Epha4に対するヒトモノクローナル抗体及びそれらの使用
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
ES2826443T3
(es)
|
2014-09-25 |
2021-05-18 |
Araxes Pharma Llc |
Inhibidores de proteínas mutantes KRAS G12C
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
EP3233829B1
(en)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
WO2016164675A1
(en)
|
2015-04-10 |
2016-10-13 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
BR112017022666A8
(pt)
|
2015-04-20 |
2022-10-18 |
Tolero Pharmaceuticals Inc |
Preparando resposta à alvocidib por perfilamento mitocondrial
|
EP3288957A4
(en)
|
2015-05-01 |
2019-01-23 |
Cocrystal Pharma, Inc. |
NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRUSES OF THE FLAVIVIIDAE FAMILY AND CANCER
|
TR201911032T4
(tr)
|
2015-05-18 |
2019-08-21 |
Tolero Pharmaceuticals Inc |
Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
|
TWI703150B
(zh)
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制menin及mll蛋白之交互作用的方法及組合物
|
JP6878316B2
(ja)
*
|
2015-06-19 |
2021-05-26 |
ノバルティス アーゲー |
Shp2の活性を阻害するための化合物および組成物
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
AU2016301315C1
(en)
|
2015-08-03 |
2022-07-07 |
Sumitomo Pharma Oncology, Inc. |
Combination therapies for treatment of cancer
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
JP2018533939A
(ja)
|
2015-10-19 |
2018-11-22 |
アラクセス ファーマ エルエルシー |
Rasの阻害剤をスクリーニングするための方法
|
CA3005089A1
(en)
|
2015-11-16 |
2017-05-26 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
SG11201804360XA
(en)
|
2015-12-03 |
2018-06-28 |
Agios Pharmaceuticals Inc |
Mat2a inhibitors for treating mtap null cancer
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
JP7306827B2
(ja)
|
2016-01-27 |
2023-07-11 |
ストロ バイオファーマ インコーポレーテッド |
抗cd74抗体コンジュゲート、抗cd74抗体コンジュゲートを含む組成物および抗cd74抗体コンジュゲートを使用する方法
|
TWI743096B
(zh)
|
2016-03-16 |
2021-10-21 |
美商庫拉腫瘤技術股份有限公司 |
Menin-mll之橋聯雙環抑制劑及使用方法
|
JP6919977B2
(ja)
|
2016-03-16 |
2021-08-18 |
クラ オンコロジー,インク. |
メニン−mllの置換された阻害剤及びその使用方法
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
CN109414596B
(zh)
|
2016-05-12 |
2023-09-29 |
密歇根大学董事会 |
Ash1l抑制剂和用其进行治疗的方法
|
US11118233B2
(en)
|
2016-05-18 |
2021-09-14 |
The University Of Chicago |
BTK mutation and ibrutinib resistance
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
US10870694B2
(en)
|
2016-09-02 |
2020-12-22 |
Dana Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2018068017A1
(en)
|
2016-10-07 |
2018-04-12 |
Araxes Pharma Llc |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
EP3362471B1
(en)
|
2016-12-19 |
2021-11-17 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Profiling peptides and methods for sensitivity profiling
|
PE20191207A1
(es)
|
2016-12-22 |
2019-09-10 |
Amgen Inc |
Benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibidores de kras g12c para tratar el cancer de pulmon, pancreatico o colorrectal
|
EP3573964A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
WO2018140598A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused n-heterocyclic compounds and methods of use thereof
|
KR102607101B1
(ko)
|
2017-01-26 |
2023-11-29 |
제트엘아이피 홀딩 리미티드 |
Cd47 항원 결합 유닛 및 그것의 사용
|
EP3573967A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
EP3573970A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
JP2020514388A
(ja)
|
2017-03-24 |
2020-05-21 |
クラ オンコロジー,インク. |
血液悪性腫瘍およびユーイング肉腫を処置するための方法
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
EP3630747A1
(en)
|
2017-05-25 |
2020-04-08 |
Araxes Pharma LLC |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
WO2018218070A2
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Covalent inhibitors of kras
|
EP3630746A1
(en)
|
2017-05-25 |
2020-04-08 |
Araxes Pharma LLC |
Compounds and methods of use thereof for treatment of cancer
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
IL272512B
(en)
|
2017-09-08 |
2022-07-01 |
Amgen Inc |
kras g12c inhibitors and methods of using them
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
WO2019055931A1
(en)
|
2017-09-18 |
2019-03-21 |
Sutro Biopharma, Inc. |
ALPHA ANTI-FOLATE ANTIBODY-RECEPTOR CONJUGATES AND USES THEREOF
|
EP3684361A4
(en)
|
2017-09-20 |
2021-09-08 |
Kura Oncology, Inc. |
MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
|
CN111655257A
(zh)
|
2017-11-10 |
2020-09-11 |
密歇根大学董事会 |
Ash1l抑制剂及用其进行治疗的方法
|
KR20210003780A
(ko)
|
2018-04-05 |
2021-01-12 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Axl 키나제 억제제 및 그의 용도
|
JP7266043B2
(ja)
|
2018-05-04 |
2023-04-27 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
US11045484B2
(en)
|
2018-05-04 |
2021-06-29 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
WO2019217691A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
CA3098885A1
(en)
|
2018-06-01 |
2019-12-05 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CN112533581A
(zh)
|
2018-06-07 |
2021-03-19 |
密歇根大学董事会 |
Prc1抑制剂及用其进行治疗的方法
|
JP7357644B2
(ja)
|
2018-06-11 |
2023-10-06 |
アムジエン・インコーポレーテツド |
がんを処置するためのkras g12c阻害剤
|
AU2019336588B2
(en)
|
2018-06-12 |
2022-07-28 |
Amgen Inc. |
KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
US11040038B2
(en)
|
2018-07-26 |
2021-06-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
|
EP3829580A1
(en)
|
2018-08-01 |
2021-06-09 |
Araxes Pharma LLC |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
WO2020060944A1
(en)
|
2018-09-17 |
2020-03-26 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
KR20210083286A
(ko)
|
2018-10-24 |
2021-07-06 |
아락세스 파마 엘엘씨 |
종양 전이를 억제하기 위한 g12c 돌연변이 kras 단백질의 억제제로서 2-(2-아크릴로일-2,6-디아자스피로[3.4]옥탄-6-일)-6-(1h-인다졸-4-일)-벤조니트릴 유도체 및 관련 화합물
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7454572B2
(ja)
|
2018-11-19 |
2024-03-22 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤及びその使用方法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
MX2021005924A
(es)
|
2018-11-29 |
2021-06-30 |
Araxes Pharma Llc |
Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
|
CA3119807A1
(en)
|
2018-12-04 |
2020-06-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
CN113226473A
(zh)
|
2018-12-20 |
2021-08-06 |
美国安进公司 |
Kif18a抑制剂
|
AU2019404576A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
EP3897855B1
(en)
|
2018-12-20 |
2023-06-07 |
Amgen Inc. |
Kif18a inhibitors
|
MA54547A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
|
CA3127502A1
(en)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
MX2021010319A
(es)
|
2019-03-01 |
2021-12-10 |
Revolution Medicines Inc |
Compuestos biciclicos de heteroarilo y usos de estos.
|
SG11202109422WA
(en)
|
2019-03-01 |
2021-09-29 |
Revolution Medicines Inc |
Bicyclic heterocyclyl compounds and uses thereof
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
CA3133460A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
AU2020280024A1
(en)
|
2019-05-21 |
2021-12-09 |
Amgen Inc. |
Solid state forms
|
US11529350B2
(en)
|
2019-07-03 |
2022-12-20 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
WO2021026100A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Pyridine derivatives as kif18a inhibitors
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CA3147272A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
JP2022542967A
(ja)
|
2019-08-02 |
2022-10-07 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
WO2021055728A1
(en)
|
2019-09-18 |
2021-03-25 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
WO2021067215A1
(en)
|
2019-09-30 |
2021-04-08 |
Agios Pharmaceuticals, Inc. |
Piperidine compounds as menin inhibitors
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
IL292438A
(en)
|
2019-10-28 |
2022-06-01 |
Merck Sharp & Dohme |
Small molecules that inhibit the g12c mutant of kras
|
JP2023515235A
(ja)
|
2019-10-31 |
2023-04-12 |
大鵬薬品工業株式会社 |
4-アミノブタ-2-エンアミド誘導体及びその塩
|
CN115873067A
(zh)
|
2019-11-04 |
2023-03-31 |
锐新医药公司 |
Ras抑制剂
|
PE20221277A1
(es)
|
2019-11-04 |
2022-09-05 |
Revolution Medicines Inc |
Inhibidores de ras
|
EP4054719A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CA3156359A1
(en)
|
2019-11-08 |
2021-05-14 |
Adrian Liam Gill |
Bicyclic heteroaryl compounds and uses thereof
|
TW202132271A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Kras g12c抑制劑化合物之改善的合成
|
TW202132296A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Kras g12c抑制劑化合物之改善的合成
|
JP2023505100A
(ja)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
共有ras阻害剤及びその使用
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
JP2023509701A
(ja)
|
2020-01-07 |
2023-03-09 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Shp2阻害剤投薬およびがんを処置する方法
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
TW202204333A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
TW202204334A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
BR112022025550A2
(pt)
|
2020-06-18 |
2023-03-07 |
Revolution Medicines Inc |
Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
|
CN116113406A
(zh)
|
2020-07-10 |
2023-05-12 |
密歇根大学董事会 |
Gas41抑制剂及其使用方法
|
JP7373664B2
(ja)
|
2020-07-15 |
2023-11-02 |
大鵬薬品工業株式会社 |
腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
|
CA3187757A1
(en)
|
2020-09-03 |
2022-03-24 |
Ethan AHLER |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
CR20230165A
(es)
|
2020-09-15 |
2023-06-02 |
Revolution Medicines Inc |
Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
KR20230170039A
(ko)
|
2021-04-13 |
2023-12-18 |
뉴베일런트, 아이엔씨. |
Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
|
KR20240004659A
(ko)
|
2021-04-30 |
2024-01-11 |
셀진 코포레이션 |
감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ras阻害剤及びその使用
|
CA3217393A1
(en)
|
2021-05-05 |
2022-11-10 |
Elena S. Koltun |
Ras inhibitors
|
AU2022268962A1
(en)
|
2021-05-05 |
2023-12-14 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
EP4347041A1
(en)
|
2021-05-28 |
2024-04-10 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
WO2023056589A1
(en)
|
2021-10-08 |
2023-04-13 |
Servier Pharmaceuticals Llc |
Menin inhibitors and methods of use for treating cancer
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
TW202412755A
(zh)
|
2022-04-25 |
2024-04-01 |
美商耐斯泰德醫療公司 |
促分裂原活化蛋白激酶(mek)抑制劑
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
TW202408589A
(zh)
|
2022-06-30 |
2024-03-01 |
美商舒卓生物製藥公司 |
抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物,及製造及使用抗ror1抗體及抗體結合物之方法
|
WO2024010925A2
(en)
|
2022-07-08 |
2024-01-11 |
Nested Therapeutics, Inc. |
Mitogen-activated protein kinase (mek) inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|